NRAS and melanoma: Combinations of targeted agents may increase efficacy in NRAS-mutant melanoma cell lines [45,46], but despite promising preclinical testing other combinations than BRAFi and MEKi have led to disappointments due to dose-limiting toxicity in phase I trials limiting their use in the clinic [31,47].